Sign up Australia
Proactive Investors - Run By Investors For Investors

Resonance Health signs deal to distribute artificial intelligence tool for diabetic retinopathy

The company's shares closed about 17% higher today, at 2.7 cents.
a human eye
Affecting 1 in 3 diabetics, diabetic retinopathy is a major complication of diabetes

Resonance Health Limited (ASX:RHT) has signed an agency agreement with TeleMedC to distribute an artificial intelligence (AI) based diabetic retinopathy (DR) grading tool.

The AI-based fully automated DR software system uses images of the eyes and clinical risk factors to provide a reading accuracy of over 92%.

These results are then reviewed by eye specialists to address the needs of those patients needing further care and treatment.

DR market is set to exceed US$11 billion by 2024

As the incidence of diabetes increases worldwide, the incidence of its complications including diabetic eye diseases is expected to rise.

Currently, an estimated 425 million people have diabetes worldwide.

Affecting 1 in 3 diabetics, DR is a major complication of diabetes which can lead to blindness if left untreated.

The DR market is set to exceed US$11 billion by 2024 according to a new research report by Global Market Insights.

Launching in Lebanon, Pakistan, and Bangladesh

Almost all vision impairment and blindness from DR can be prevented through effective diabetes management and screening programs.

Resonance Health in conjunction with TeleMedC is aiming to provide DR screenings for large populations via primary healthcare providers at an affordable price.

The company will commercialise first in Lebanon, Pakistan, and Bangladesh and is currently working with TeleMedC on gaining appropriate regulatory clearances.


View full RHT profile View Profile

Resonance Health Ltd Timeline

Related Articles

June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use